Ignite Creation Date:
2025-12-25 @ 12:58 AM
Ignite Modification Date:
2026-01-02 @ 2:41 AM
Study NCT ID:
NCT05241093
Status:
RECRUITING
Last Update Posted:
2025-04-10
First Post:
2022-01-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor:
Tarapeutics Science Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-29
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-16
First Submit QC Date:
None
Study First Post Date:
2022-02-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-09
Last Update Post Date:
2025-04-10
Last Update Post Date Type:
ACTUAL